moderate to severe rheumatoid arthritis in adult patients who have had an inadequate response to methotrexate

Rinvoq (upadacitinib) is a prescription medication that treats moderate to severe rheumatoid arthritis by blocking inflammation at the source through the inhibition of Janus kinase (JAK). It is taken orally once a day, and dosage may vary per patient. Clinical trials confirm its efficacy, with over 70% of patients who failed other therapies showing a significant reduction in symptoms. However, Rinvoq may cause minor side effects, like upper respiratory infections, and serious side effects are rare but possible. Healthcare providers must monitor patients for potential side effects, especially when taken with prohibited medications. Despite possible side effects, Rinvoq offers promising treatment that enhances symptom relief and elevates the patient’s quality of life.